Core Viewpoint - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant, leading to a significant drop in its stock price [1][2][3]. Group 1: Company Developments - On December 31, 2025, Corcept announced it received a Complete Response Letter (CRL) from the FDA, denying approval for relacorilant as a treatment for hypertension secondary to hypercortisolism [2]. - The FDA acknowledged previous trial results but required additional evidence of effectiveness for a favorable benefit-risk assessment [2]. Group 2: Market Reaction - Following the FDA's announcement, Corcept's stock price fell by $31.42, a decrease of 44.76%, opening at $38.78 per share, marking a new 52-week low [3]. - This stock price drop reflects levels not seen since September 2024, indicating a significant market reaction to the FDA's decision [3].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into Live Nation Entertainment, Inc. for potential breaches of fiduciary duties and violations of federal securities laws [1] Group 1: Investigation Details - The investigation follows a class action complaint alleging that Live Nation made materially false and misleading statements and failed to disclose adverse facts about its business and operations [2] - Specific allegations include that Live Nation engaged in anticompetitive conduct, such as charging high fees and retaliating against venues, which could lead to regulatory scrutiny and reputational harm [2] Group 2: Shareholder Rights - Current stockholders who held Live Nation stock before February 23, 2022, are encouraged to contact Johnson Fistel to discuss their legal rights regarding the investigation [3]

Core Viewpoint - The Schall Law Firm is investigating Hims & Hers Health, Inc. for potential violations of securities laws following a significant drop in share price due to allegations of illegal practices and misleading marketing [1][2]. Group 1: Investigation Details - The investigation centers on whether Hims & Hers made false or misleading statements and failed to disclose critical information to investors [2]. - Novo Nordisk announced the termination of its relationship with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. - Following the announcement from Novo Nordisk, Hims & Hers shares plummeted by over 32.4% in afternoon trading [2]. Group 2: Company Background - Hims & Hers Health, Inc. is involved in telehealth services and has faced scrutiny regarding its compliance with laws governing the sale of compounded drugs [2]. - The FDA has resolved a shortage of Wegovy® and confirmed that Novo Nordisk is meeting the demand, which has implications for Hims & Hers' business practices [2].